MedTrace Logo

Comparison of the Efficacy, Safety, and Relapse of ECT to ECT Plus Agomelatine for Depressed Patients

NCT04181567 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2019-11-29

No results posted yet for this study

Summary

Our hypothesis is that using antidepressants during the ECT has a better efficacy and longer time to relapse/recurrence to the ECT without antidepressants. The purpose of this study is to compare the efficacy, safety, and time to relapse/recurrence of ECT to ECT plus agomelatine in the treatment of patients with major depressive disorder. Inpatients with major depressive disorder for ECT will be randomly assigned to double-blind treatment with placebo or agomelatine 50 mg/d.

Conditions

Interventions

OTHER

electroconvulsive therapy

electroconvulsive therapy 2 times weekly

DRUG

agomelatine

agomelatine

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Department of Health, Executive Yuan, R.O.C. (Taiwan)

    collaborator OTHER_GOV

  • Ministry of Science and Technology, Taiwan

    collaborator OTHER_GOV

  • Kaohsiung Kai-Suan Psychiatric Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-03
Primary Completion
2019-10-08
Completion
2019-11-22

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04181567 on ClinicalTrials.gov